In the last trading session, 3,545,354 Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares changed hands as the company’s beta touched 3.01. With the company’s per share price at $2.96 changed hands at -$0.06 or -0.02% during last session, the market valuation stood at $301.41 Million. SEEL’s last price was a discount, traded about -122.97% off its 52-week high of $6.6. The share price had its 52-week low at $0.56, which suggests the last value was 81.08% up since then. When we look at Seelos Therapeutics, Inc.’s average trading volume, we note the 10-day average is 2.78 Million shares, with the 3-month average coming to 5.29 Million.
Analysts gave the Seelos Therapeutics, Inc. (SEEL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2. If we narrow down to specifics, the data shows that none out of 5 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, 1 recommended SEEL as a Hold, 4 felt it is a Buy and none rated the stock as Underweight. Seelos Therapeutics, Inc.’s EPS for the current quarter is expected to be -$0.13.
Seelos Therapeutics, Inc. (NASDAQ:SEEL) trade information
Although SEEL has turned red as seen at the end of in last trading. With action -1.99%, the performance over the past five days has been red. The jump to weekly highs of $3.40- on Tuesday, Jun 15 added 12.94% to the stock’s daily price. The company’s shares are showing year-to-date upside of 0.87%, with the 5-day performance at -0.13% in the red. However, in the 30-day time frame, Seelos Therapeutics, Inc. (NASDAQ:SEEL) is -0.09% down. Looking at the short shares, we see there were 3.62 Million shares sold at short interest cover period of 0.68 days.
The consensus price target for the stock as assigned by Wall Street analysts is $9.8, meaning bulls need an upside of 231.08% from its current market value. According to analyst projections, SEEL’s forecast low is $4 with $15 as the target high. To hit the forecast high, the stock’s price needs a +406.76% upsurge from its current level, while the stock would need to tank 35.14% for it to hit the projected low.
Seelos Therapeutics, Inc. (SEEL) estimates and forecasts
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 67.3%. The 2021 estimates are for Seelos Therapeutics, Inc. earnings to increase by 83.1%, but the outlook for the next 5-year period is at 0% per year.
Seelos Therapeutics, Inc. (NASDAQ:SEEL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.85% of Seelos Therapeutics, Inc. shares while 26.52% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 27.87%. There are 76 institutions holding the Seelos Therapeutics, Inc. stock share, with Invesco Ltd. the top institutional holder. As of Mar 30, 2021, the company held 4.41% of the shares, roughly 3.46 Million SEEL shares worth $17.29 Million.
Vanguard Group, Inc. (The) holds the second largest percentage of outstanding shares, with 3.72% or 2.92 Million shares worth $14.58 Million as of Mar 30, 2021.
Among Mutual Funds, the top two as of May 30, 2021 were Invesco ETF Tr-Invesco DWA Healthcare Momentum ETF and Vanguard Total Stock Market Index Fund. With 3194254 shares estimated at $9.84 Million under it, the former controlled 4.06% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.21% of the shares, roughly 1.74 Million shares worth around $8.68 Million.